AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$ATR

Vinczeller Shiela sold $100K of ATR

Vinczeller Shiela (Chief Human Resources Officer) sold 765 shares of APTARGROUP, INC. (ATR) at $130.37 on 2026-09-02.

Original reporting
SEC EDGAR · Vinczeller Shiela
Published Sep 3, 2026, 4:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 4:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ATR
Bearish
medium confidence
Mentioned
$ATR
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATRBearishLow
01

Why it matters

Provides fresh primary data on insider activity.

02

Market read

Insider sale of ~0.3% of holdings may slightly affect ATR's stock perception.

03

What to watch

Sale represents less than 1% of total holdings.

Relevance 3/10Novelty 4/10Timing: filing today

Background

Form 4 filing discloses insider transactions required by SEC.

Company-level read

Ticker impact

$ATRBearishMedium confidence
Context

Chief Human Resources Officer sold 765 shares for $99,732, indicating insider selling pressure.

Expected impact

Modest price dip expected in near term.

Evidence & confidence

Sale size is modest relative to holdings but signals possible concerns.

Market effects

Sector

Minimal impact on biotech sector.

Regional

None.

Global

Low.

Counterpoint

What could challenge this read

Insider sale may be routine portfolio rebalancing, not a red flag.

Key entities

  • Company
    Aptargroup, Inc.

    Biotech firm listed on NYSE under ticker ATR.

  • Person
    Vinczeller Shiela

    Chief Human Resources Officer of Aptargroup.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ATR insider trading history →

Related articles

$ATRHighAI 8/10

Aptar Q3 2026 slides: broad growth, strong Pharma pipeline

AptarGroup (NYSE:ATR) reported Q3 2026 sales of $1.019B, up 6% YoY, with adjusted EPS of $1.52 beating estimates. Growth was seen across all segments, but margins were pressured. The Pharma segment grew 2% reported, 1% core, while Beauty grew 9% reported, 8% core, and Closures grew 11%. Management expects Q4 adjusted EPS of $1.39-$1.47, up 17% YoY.

investing.com
$ATRMed

AptarGroup Inc (ATR) (Q3 2026) Earnings Call Highlights: Core Sales Grow 5% as Pharma

AptarGroup Inc (ATR) reported Q3 2026 core sales growth of 5% across all segments, with Pharma, Beauty, and Closures up 8%, 8%, and 11% respectively. Adjusted EPS was $1.52, down 6% YoY. Pharma growth was impacted by emergency medicine destocking, expected to affect full-year sales by $65M. Beauty and Closures margins declined due to operational challenges. CEO Gael Touya outlined plans for multi-year transformation in Beauty and reiterated long-term growth targets for Pharma.

finance.yahoo.com
$ATRMedAI 8/10

What AptarGroup (ATR) Said on Its Q3 Earnings Call

AptarGroup (ATR) reported Q3 earnings, highlighting growth in beauty, closures, and pharma sectors. Beauty core sales rose 8%, while closures saw 11% growth. Pharma developments include collaborations and acquisitions. The company recorded a $61.2M charge related to its Russian subsidiary. ATR forecasted Q4 adjusted EPS of $1.39-$1.47, up 17% YoY. Full-year capex is expected at $260M-$280M. Virginie Maes will lead Aptar Pharma starting January 1.

finance.yahoo.com